塞尔帕替尼与普拉替尼在融合阳性非小细胞肺癌中的匹配调整间接比较
Matching-adjusted indirect comparison of selpercatinib and pralsetinib in fusion-positive non-small cell lung cancer.
作者信息
Hochmair Maximilian, Kiiskinen Urpo, D'yachkova Yulia, Puri Tarun, Wang Xuwen, Wolowacz Sorrel, Vickers Adrian, Nadal Ernest
机构信息
Department of Respiratory & Critical Care Medicine, Karl Landsteiner Institute of Lung Research & Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria.
Eli Lilly and Company, Indianapolis, IN, USA.
出版信息
Future Oncol. 2025 Jun;21(15):1867-1878. doi: 10.1080/14796694.2025.2508132. Epub 2025 Jun 3.
AIMS
Selpercatinib and pralsetinib are approved for RET-rearranged non - small cell lung cancer.
MATERIALS & METHODS: Efficacy and safety were compared using matching-adjusted indirect comparison.
RESULTS
Median progression-free survival (PFS) was 22.1 and 13.3 months for selpercatinib and pralsetinib, respectively (HR = 0.67; 95% CI, 0.53-0.85). Objective response rate was 64.5% and 65.8%, and disease control rate was 92.1% and 90.4%, respectively. Median overall survival was not reached for selpercatinib and 43.9 months for pralsetinib (HR = 0.81; 95% CI, 0.60-1.09). Grade ≥ 3 treatment-related adverse events (TRAEs) were reported in 39.3% and 62.6% of patients, with discontinuations due to TRAEs in 3.6% and 10.0% of patients, respectively.
CONCLUSION
Outcomes were similar; however, PFS was significantly prolonged with selpercatinib, with fewer grade ≥ 3 TRAEs.
目的
塞尔帕替尼和普拉替尼已被批准用于治疗RET重排的非小细胞肺癌。
材料与方法
采用匹配调整间接比较法比较疗效和安全性。
结果
塞尔帕替尼和普拉替尼的中位无进展生存期（PFS）分别为22.1个月和13.3个月（HR = 0.67；95%CI，0.53 - 0.85）。客观缓解率分别为64.5%和65.8%，疾病控制率分别为92.1%和90.4%。塞尔帕替尼的中位总生存期未达到，普拉替尼为43.9个月（HR = 0.81；95%CI，0.60 - 1.09）。39.3%和62.6%的患者报告了≥3级治疗相关不良事件（TRAEs），因TRAEs停药的患者分别为3.6%和10.0%。
结论
结果相似；然而，塞尔帕替尼显著延长了PFS，且≥3级TRAEs较少。
Zotero 插件